Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. حسب Hongliang Chen (538815)

Baseline patient characteristics. حسب Oscar F. C. van den Bosch (22184246)

"…Their median baseline variabilities of respiratory rate and tidal volume were 0.19 (IQR: 0.16–0.25) and 0.23 (0.19–0.34), respectively. While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …"

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

A summary of calibration standards (n = 3). حسب Ewa Paszkowska (21246702)

"…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …"

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. حسب Montserrat Llanses Martinez (17797522)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

A summary of the included study characteristics. حسب Zahra Tajik (20752452)

الموضوعات:

Loss of Vps34 is associated with decreased eTreg survival but intact activation. حسب Erienne G. Norton (9612079)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Linear regression analysis. حسب Young Kyu Lee (14076058)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Boxplot of Patient-centered care scores as a function of Time. حسب Thales Guardia de Barros (22216025)

الموضوعات:

Naringenin decreases mitochondrial function. حسب Lauren A. Eanes (20995499)

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. حسب Justine Guguin (9088672)

Naringenin decreases total cell viability. حسب Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. حسب Sonia T. Gazeau (21512764)